ALKS

Alkermes plc Ordinary Shares (ALKS)

Stock · NASDAQ · Health Care

$41.22as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 6, 2026

Baird Highlights Growth Potential for Alkermes plc (ALKS). Baird has highlighted Alkermes plc as a company with promising growth potential, citing its pipeline and recent developments. A Yahoo article compares Alkermes to LQDA, discussing which biotech may be more attractive for investors. The stock is currently trading near its 200‑day moving average and close to a key support level of $48.74, while analysts average a target of $56.56.

Price chart

Open in TradingView

Active signals

200 SMA Touch87.7%
Resistance level
$48.47
Industry
Biotechnology: Pharmaceutical Preparations

ALKS Signal Track Record

How signals performed across all stocks →

What ALKS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike37+2.2%57%
200-Day Moving Average TouchActive now29+2.2%55%
Bollinger Band Breakout24+1.6%58%
Bollinger Band Breakdown19-2.9%47%
Any 20-session window (baseline)+0.4%52%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About ALKS

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinica…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
2,050

Fundamentals

1-day range
$39.71$41.57
Market cap
$8.11B
P/E (trailing)
99.15
P/E (forward)
22.80
EPS (trailing)
$0.38
Dividend yield
—
Beta
0.25
Avg. volume
1.86M
52-week range
$27$55.67
Next earnings: October 28, 2026 · EPS estimate $0.25confirmed

How Alkermes plc Ordinary Shares Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$1.48BNet Income$241.66M (16%)SG&A$701.52M (48%)R&D$323.96M (22%)Cost of Revenue$196.46M (13%)Tax$49.79M (3%)ALKS

Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub

Gross Profit$1.28B(87%)
Operating Income$253.96M(17%)

Forecasts

19 analyst ratings

Buy 76%
Hold 20%
Sell 4%
1-year price forecast
High
$83
+101.4%
Median
$58
+40.7%
Low
$38
-7.8%

Alkermes plc Ordinary Shares Competitors

Chosen by industry and closest market cap.

  • ALKS
    Alkermes plc Ordinary Shares
    $41.22
    ▲ 2.79%
    Market cap $8.11BP/E 99.15
    $27$55.67
  • LQDA
    Liquidia Corporation Common Stock
    $34.35
    ▼ 1.24%
    Market cap $7.95BP/E 22.46
    $21.94$93.61
  • RYTM
    Rhythm Pharmaceuticals Inc. Common Stock
    $86.17
    ▼ 2.05%
    Market cap $7.72BP/E —
    $74.5$122.2
  • TGTX
    TG Therapeutics Inc. Common Stock
    $53.97
    ▼ 3.62%
    Market cap $7.59BP/E 19.42
    $26.76$59.3
  • IONS
    Ionis Pharmaceuticals Inc. Common Stock
    $42.94
    ▼ 2.67%
    Market cap $9.06BP/E —
    $42.08$86.74
  • COGT
    Cogent Biosciences Inc. Common Stock
    $29.52
    ▲ 0.03%
    Market cap $7.14BP/E —
    $13.78$43.73
  • SYRE
    Spyre Therapeutics Inc. Common Stock
    $79.9
    ▼ 0.25%
    Market cap $9.12BP/E —
    $21.01$110.18

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
289.8K
Disposed
69.2K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.